USFDA concludes inspection at synthetic peptide API facility of Aurobindo Pharma’s arm

16 Feb 2024 Evaluate

United States Food and Drug Administration (USFDA) has concluded the inspection at synthetic peptide API facility of Auro Peptides, a subsidiary of Aurobindo Pharma. The said inspection conducted from February 12 to February 16, 2024. The inspection was concluded with zero observations. 

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1175.80 -9.70 (-0.82%)
16-Dec-2025 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1782.80
Dr. Reddys Lab 1279.00
Cipla 1500.00
Zydus Lifesciences 913.90
Lupin 2085.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×